Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

Circular RNA vaccines encoding Pvs25 induce antibodies that block Plasmodium vivax transmission

Academic source · Vaccine

Source published:

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What the paper reports

Circular RNA nanoparticles encoding the malaria transmission antigen Pvs25 were compared with a modified linear mRNA vaccine in mice. Both platforms induced antigen-specific responses, and booster immunization generated antibodies that blocked parasite development in mosquito assays. The findings support further evaluation of circular RNA for transmission-blocking vaccination, without establishing greater efficacy, durability, or manufacturing economy than linear mRNA in humans.

Why this paper is included

Extends circular RNA vaccine evidence beyond common viral targets; mouse immunogenicity and mosquito assays require confirmation in larger animals and humans.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP

Related updates

Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNPAsk AI ↗
Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

mRNA / LNP Clinical Pharmacology & Model-Informed DevelopmentAsk AI ↗
Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.

mRNA / LNPAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗